Search Results

You are looking at 101 - 110 of 1,651 items for :

  • "chemotherapy" x
Clear All
Full access

Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou and Rudolph M. Navari

Background: Avoiding acute care services can improve cancer care and reduce cost. The US Centers for Medicare and Medicaid Services’ (CMS) new oncology outcome measure (OP-35) defines 30-day post-chemotherapy inpatient (IP) and/or emergency

Full access

Adrienne G. Waks and Ann H. Partridge

heterogeneity in outcomes between patients, and only limited research has identified important patient-specific determinants beyond age. In one retrospective study of premenopausal patients with breast cancer, the odds ratio of developing chemotherapy

Full access

Pelin Cinar and Andrew H. Ko

treatment options for patients with locally advanced unresectable PDAC Explain the roles of systemic therapy and chemoradiation for locally advanced PDAC including optimal sequencing, recent improvements in chemotherapy, and whether radiotherapy improves

Full access

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis and for the Platinum Study Group

recurrent disease will typically require cisplatin-based chemotherapy. Although testicular cancer survivors (TCS) can now expect to live for >40 years after diagnosis, 3 they are at risk for short- and long-term complications related to cancer therapy

Full access

Robert C. Stillman and Emily Konerman

, the hospital services 175 ambulatory infusion chairs. Each month, we administer over 6,000 chemotherapy infusions on an IV pump. Smart IV pumps in tandem with hospital information technology infrastructure integrate IV drug administration pump data

Full access

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru and Saby George

-based neoadjuvant chemotherapy has been shown to improve survival in patients with localized muscle-invasive bladder cancer. 2 - 5 In the metastatic setting, gemcitabine/cisplatin (GC) showed similar efficacy to MVAC (methotrexate

Full access

Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel and Joseph A. Greer

Symptom prevalence has been described mostly in patients receiving intravenous chemotherapy or patients with breast cancer on adjuvant endocrine therapy. 8 , 9 Because patients on oral therapy do not receive the same degree of oversight and monitoring as

Full access

Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas and Lynne I. Wagner

Overview Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. 1 – 10 The symptom

Full access

Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre and James Rosberg

consulting contract with Analysis Group. None of the authors have individual conflicts of interest. References 1 Coiffier B Guastalla JP Pujade-Lauraine E . Predicting cancer-associated anemia in patients receiving non-platinum chemotherapy

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud and Brant A. Inman

initial presentation, 75% to 85% are non–muscle-invasive bladder cancers (NMIBCs), which include stages Ta, T1, and Tis. 2 Several studies have shown a benefit of immediate intravesical chemotherapy (IVC) after transurethral resection (TUR) in reducing